See All Slides - tctmd.com

Slides

Presentation SCCT 2017

Contrast and Radiation Safety: Dose Reporting, Monitoring and the Role of Dose Registries

Presenter: Ed Nicol

July 11, 2017

Presentation SCCT 2017

Non-obstructive Disease on Cardiovascular CT Should not Affect Primary Prevention

Presenter: Rita F. Redberg

July 10, 2017

Presentation SCCT 2017

CTA and CT-FFR as the Gatekeeper to the Cath Lab

Presenter: Hasan Jilaihawi

July 09, 2017

Presentation

TAVR With or Without PCI Strategy

July 05, 2017

Presentation

Temporal Trends in TAVR: From FRANCE 2 (2010-2012) to FRANCE TAVI (2013-2015)

June 26, 2017

Presentation

Trends and Outcomes of Off-Label Use of TAVR in 23,847 Patients in TVT Registry

June 22, 2017

Presentation TVT 2017

Will the Heart Team Survive the Modern Era of Minimalist TAVR?

Presenter: Martin B. Leon, Hendrik Treede, Wilson Y. Szeto

June 16, 2017

Presentation TVT 2017

A Surgeons Viewpoint on SAVR vs TAVR Bioprosthetic Valve Durability

Presenter: Martin B. Leon, Hendrik Treede

June 16, 2017

Presentation TVT 2017

Hemodynamic Trends on Serial Echocardiograms After TAVR: Comprehensive 5-Year Analyses From the PARTNER 1 Trials

Presenter: Martin B. Leon, Hendrik Treede, Philippe Pibarot

June 16, 2017

Presentation TVT 2017

The Latest in TAVR Adjunctive Pharmacotherapy: The Case for Routine vs Selective Anticoagulant Therapy

Presenter: Martin B. Leon, Hendrik Treede, George D. Dangas

June 16, 2017

Advertisement

Slides

Contrast and Radiation Safety: Dose Reporting, Monitoring and the Role of Dose Registries

Non-obstructive Disease on Cardiovascular CT Should not Affect Primary Prevention

CTA and CT-FFR as the Gatekeeper to the Cath Lab

TAVR With or Without PCI Strategy

Temporal Trends in TAVR: From FRANCE 2 (2010-2012) to FRANCE TAVI (2013-2015)

Trends and Outcomes of Off-Label Use of TAVR in 23,847 Patients in TVT Registry

Will the Heart Team Survive the Modern Era of Minimalist TAVR?

A Surgeons Viewpoint on SAVR vs TAVR Bioprosthetic Valve Durability

Hemodynamic Trends on Serial Echocardiograms After TAVR: Comprehensive 5-Year Analyses From the PARTNER 1 Trials

The Latest in TAVR Adjunctive Pharmacotherapy: The Case for Routine vs Selective Anticoagulant Therapy

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content